|
US8212004B2
(en)
*
|
1999-03-02 |
2012-07-03 |
Human Genome Sciences, Inc. |
Neutrokine-alpha fusion proteins
|
|
US6812327B1
(en)
*
|
1996-10-25 |
2004-11-02 |
Human Genome Sciences, Inc. |
Neutrokine-alpha polypeptides
|
|
GB9828628D0
(en)
|
1998-12-23 |
1999-02-17 |
Glaxo Group Ltd |
Novel ligand
|
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
US20030095967A1
(en)
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
|
US20050100548A1
(en)
*
|
2001-07-24 |
2005-05-12 |
Biogen Idec Ma Inc. |
BAFF, inhibitors thereof and their use in the modulation of B-cell response
|
|
WO2000068378A1
(en)
|
1999-05-06 |
2000-11-16 |
National Jewish Medical And Research Center |
Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
|
|
UA75049C2
(uk)
*
|
1999-08-17 |
2006-03-15 |
Байоджен Айдек Ма Інк. |
Фармацевтична композиція, що містить поліпептид, який являє собою білковий фактор дозрівання в-клітин (всма), що зв'язується з фактором активації в-клітин (baff), спосіб інгібування росту в-клітин, спосіб лікування аутоімунного захворювання, спосіб лікування гіпертонії, спосіб інгібування запалення та спосіб модулювання імунної відповіді у ссавця за допомогою всма
|
|
UA74798C2
(uk)
|
1999-10-06 |
2006-02-15 |
Байоджен Айдек Ма Інк. |
Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
|
|
CA2396793A1
(en)
*
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US7371388B1
(en)
*
|
2000-05-04 |
2008-05-13 |
Human Genome Sciences, Inc. |
Treatment of Sjogren's syndrome by administration of TR18 polypeptides
|
|
US20020086018A1
(en)
*
|
2000-05-12 |
2002-07-04 |
Theill Lars Eyde |
Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
|
|
AU2001268427B2
(en)
|
2000-06-16 |
2007-03-29 |
Glaxosmithkline Intellectual Property Limited |
Antibodies that immunospecifically bind to blys
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
WO2002016411A2
(en)
|
2000-08-18 |
2002-02-28 |
Human Genome Sciences, Inc. |
Binding polypeptides and methods based thereon
|
|
UA83458C2
(uk)
*
|
2000-09-18 |
2008-07-25 |
Байоджен Айдек Ма Інк. |
Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
|
|
DE10049010A1
(de)
*
|
2000-10-04 |
2002-04-18 |
Boehringer Ingelheim Int |
Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
|
|
BRPI0209933B8
(pt)
|
2001-05-24 |
2021-05-25 |
Zymogenetics Inc |
proteína de fusão, e, molécula de ácido nucleico
|
|
BR0211614A
(pt)
*
|
2001-08-03 |
2006-10-31 |
Genentech Inc |
polipeptìdeo tacis e br3 e empregos dos mesmos
|
|
AU2003221256A1
(en)
*
|
2002-02-21 |
2003-09-09 |
Biogen Idec Ma Inc. |
Use of bcma as an immunoregulatory agent
|
|
CN1692127A
(zh)
*
|
2002-07-25 |
2005-11-02 |
健泰科生物技术公司 |
Taci抗体及其用途
|
|
WO2004094620A2
(en)
*
|
2003-03-28 |
2004-11-04 |
Biogen Idec Ma Inc. |
Truncated baff receptors
|
|
PL1631313T3
(pl)
*
|
2003-06-05 |
2015-08-31 |
Genentech Inc |
Terapia skojarzona zaburzeń z komórek B
|
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
AU2004285455A1
(en)
|
2003-10-20 |
2005-05-12 |
Biogen Idec Ma Inc. |
Therapeutic regimens for BAFF antagonists
|
|
CA2554526A1
(en)
*
|
2004-01-29 |
2005-08-18 |
Genentech, Inc. |
Variants of the extracellular domain of bcma and uses thereof
|
|
CA2585927A1
(en)
*
|
2004-11-04 |
2006-05-18 |
Genentech, Inc. |
Polypeptides that bind baff and/or april
|
|
WO2006067210A1
(en)
*
|
2004-12-23 |
2006-06-29 |
Laboratoires Serono S.A. |
Bcma polypeptides and uses thereof
|
|
AU2006209237B2
(en)
*
|
2005-01-28 |
2010-06-24 |
Biogen Ma Inc. |
Use of BAFF to treat Th2-mediated conditions
|
|
EP1922079A2
(en)
|
2005-08-09 |
2008-05-21 |
ZymoGenetics, Inc. |
Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
|
|
AU2006278229B2
(en)
|
2005-08-09 |
2011-10-27 |
Ares Trading S.A. |
Methods for treating B-cell malignancies using TACI-Ig fusion molecule
|
|
EA015860B1
(ru)
*
|
2005-10-13 |
2011-12-30 |
Хьюман Дженом Сайенсиз, Инк. |
Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
|
WO2007062090A2
(en)
|
2005-11-23 |
2007-05-31 |
Genentech, Inc. |
Methods and compositions related to b cell assays
|
|
US8211649B2
(en)
|
2006-03-31 |
2012-07-03 |
Human Genome Sciences, Inc. |
Methods of diagnosing and prognosing hodgkin's lymphoma
|
|
JP2009537563A
(ja)
|
2006-05-15 |
2009-10-29 |
アレス トレーディング ソシエテ アノニム |
Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
|
|
KR101314369B1
(ko)
*
|
2008-07-17 |
2013-10-10 |
노파르티스 아게 |
치료학적 항체에 대한 조성물 및 사용 방법
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
WO2010093993A2
(en)
*
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
|
EP2406284B9
(en)
|
2009-03-10 |
2017-03-01 |
Biogen MA Inc. |
Anti-bcma antibodies
|
|
US8728730B2
(en)
|
2009-09-03 |
2014-05-20 |
Genentech, Inc. |
Methods for treating, diagnosing, and monitoring rheumatoid arthritis
|
|
CN101781680B
(zh)
*
|
2009-10-19 |
2012-05-09 |
南通大学附属医院 |
测定对人baff-r基因启动子活性影响因素的方法
|
|
WO2011108008A2
(en)
*
|
2010-03-04 |
2011-09-09 |
Transgene Biotek Ltd. |
Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
|
|
BR112013021725A2
(pt)
|
2011-02-28 |
2016-11-01 |
Genentech Inc |
marcadores biológicos e métodos para prever resposta aos antagonistas de células b
|
|
UA112434C2
(uk)
|
2011-05-27 |
2016-09-12 |
Ґлаксо Ґруп Лімітед |
Антигензв'язувальний білок, який специфічно зв'язується з всма
|
|
CA2833820C
(en)
*
|
2011-05-27 |
2019-10-29 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) -binding proteins
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
KR20140119777A
(ko)
|
2012-01-31 |
2014-10-10 |
제넨테크, 인크. |
항-ig-e m1'' 항체 및 그의 사용 방법
|
|
WO2015100246A1
(en)
|
2013-12-24 |
2015-07-02 |
Ossianix, Inc. |
Baff selective binding compounds and related methods
|
|
CN106459990B
(zh)
|
2014-02-07 |
2021-06-01 |
麦克马斯特大学 |
三功能t细胞抗原偶联物及其制备方法和用途
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
AU2015357526B2
(en)
|
2014-12-05 |
2022-03-17 |
Eureka Therapeutics, Inc. |
Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
|
|
KR20240135036A
(ko)
*
|
2014-12-05 |
2024-09-10 |
메모리얼 슬로안 케터링 캔서 센터 |
B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
PL3988117T3
(pl)
|
2015-04-13 |
2025-03-10 |
Pfizer Inc. |
Przeciwciała terapeutyczne i ich zastosowania
|
|
EP3283520B1
(en)
|
2015-04-13 |
2020-05-06 |
Pfizer Inc |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
US10711282B2
(en)
|
2015-11-23 |
2020-07-14 |
Novartis Ag |
Optimized lentiviral transfer vectors and uses thereof
|
|
AU2016382512A1
(en)
|
2015-12-30 |
2018-07-12 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
US20170233484A1
(en)
|
2016-02-17 |
2017-08-17 |
Seattle Genetics, Inc. |
Bcma antibodies and use of same to treat cancer and immunological disorders
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
CN116041514A
(zh)
|
2016-06-06 |
2023-05-02 |
希望之城 |
Baff-r抗体及其用途
|
|
CA3029209A1
(en)
|
2016-06-21 |
2017-12-28 |
Teneobio, Inc. |
Cd3 binding antibodies
|
|
FI4050034T3
(fi)
|
2016-09-14 |
2024-06-10 |
Teneoone Inc |
Cd3:een sitoutuvia vasta-aineita
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
NZ754713A
(en)
|
2016-12-21 |
2025-11-28 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
MX2019013514A
(es)
|
2017-05-12 |
2020-01-20 |
Crispr Therapeutics Ag |
Materiales y metodos para modificar celulas por ingenieria genetica y usos de los mismos en inmunooncologia.
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
IL271194B2
(en)
|
2017-06-20 |
2024-10-01 |
Teneobio Inc |
Anti-bcma heavy chain-only antibodies
|
|
SG11201913137VA
(en)
|
2017-07-11 |
2020-01-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
WO2019071358A1
(en)
|
2017-10-12 |
2019-04-18 |
Mcmaster University |
Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
|
|
JP7585034B2
(ja)
|
2017-10-18 |
2024-11-18 |
ノバルティス アーゲー |
選択的タンパク質分解のための組成物及び方法
|
|
EP3700933A1
(en)
|
2017-10-25 |
2020-09-02 |
Novartis AG |
Antibodies targeting cd32b and methods of use thereof
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
JP7447006B2
(ja)
|
2017-11-01 |
2024-03-11 |
ジュノー セラピューティクス インコーポレイテッド |
Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
|
|
AU2018358067A1
(en)
|
2017-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
|
|
SG11202003427XA
(en)
|
2017-11-06 |
2020-05-28 |
Juno Therapeutics Inc |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
SG11202004512XA
(en)
|
2017-11-15 |
2020-06-29 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
|
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
BR112020010579A2
(pt)
|
2017-11-30 |
2020-11-10 |
Novartis Ag |
receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
|
|
TW201930591A
(zh)
|
2018-01-08 |
2019-08-01 |
瑞士商諾華公司 |
用於與嵌合抗原受體療法併用之免疫增強rna
|
|
EP3737692A4
(en)
|
2018-01-09 |
2021-09-29 |
Elstar Therapeutics, Inc. |
CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
US12227763B2
(en)
|
2018-05-11 |
2025-02-18 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
UY38251A
(es)
|
2018-06-01 |
2019-12-31 |
Novartis Ag |
Moléculas de unión contra bcma y usos de las mismas
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
MD4324851T2
(ro)
|
2018-07-19 |
2025-12-31 |
Regeneron Pharma |
Receptori antigenici chimerici cu specificitate BCMA și utilizările acestora
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
CA3109959A1
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
KR20210113169A
(ko)
|
2018-11-01 |
2021-09-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Β세포 성숙 항원에 특이적인 키메라 항원 수용체를 이용한 치료 방법
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
JP7710373B2
(ja)
|
2019-02-21 |
2025-07-18 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
JP7776987B2
(ja)
|
2019-04-05 |
2025-11-27 |
テネオバイオ， インコーポレイテッド |
Ｐｓｍａに結合する重鎖抗体
|
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
US20220249558A1
(en)
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
PE20220568A1
(es)
|
2019-05-21 |
2022-04-20 |
Novartis Ag |
Moleculas de union a cd19 y usos de las mismas
|
|
CN114206927B
(zh)
|
2019-06-14 |
2025-03-21 |
特尼奥生物股份有限公司 |
与cd22和cd3结合的多特异性重链抗体
|
|
JP2022539248A
(ja)
|
2019-07-02 |
2022-09-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
組換えａｄ３５ベクター及び関連遺伝子治療改善
|
|
PH12022551291A1
(en)
|
2019-11-26 |
2023-11-20 |
Novartis Ag |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
MX2022007759A
(es)
|
2019-12-20 |
2022-07-19 |
Novartis Ag |
Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
|
|
CN116234829A
(zh)
|
2020-01-03 |
2023-06-06 |
马伦戈治疗公司 |
抗tcr抗体分子及其用途
|
|
KR20220147109A
(ko)
|
2020-02-27 |
2022-11-02 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
|
KR20220146530A
(ko)
|
2020-02-27 |
2022-11-01 |
노파르티스 아게 |
키메라 항원 수용체-발현 세포의 제조 방법
|
|
AU2021263448B2
(en)
|
2020-04-29 |
2026-02-05 |
Teneobio, Inc. |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
|
IL299827B1
(en)
|
2020-07-15 |
2026-04-01 |
Cerebral Therapeutics Inc |
A medical system that includes two access ports
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN116406371A
(zh)
*
|
2020-08-12 |
2023-07-07 |
斯坦福大学托管董事会 |
sBCMA变体及其Fc融合蛋白
|
|
US20230302155A1
(en)
|
2020-08-21 |
2023-09-28 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CA3214757A1
(en)
|
2021-04-08 |
2022-10-13 |
Andreas Loew |
Multifuntional molecules binding to tcr and uses thereof
|
|
EP4330381A1
(en)
|
2021-04-27 |
2024-03-06 |
Novartis AG |
Viral vector production system
|
|
CA3173810A1
(en)
|
2021-06-01 |
2022-12-01 |
Andreas Bader |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
AU2022327178A1
(en)
|
2021-08-11 |
2024-03-28 |
Akso Biopharmaceutical, Inc. |
METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF
|
|
JP2024531364A
(ja)
|
2021-08-20 |
2024-08-29 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
|
US12605537B2
(en)
|
2022-02-15 |
2026-04-21 |
Biogen Ma Inc. |
Implantable medical device for use with or having recording electrode
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
CN120112650A
(zh)
|
2022-10-26 |
2025-06-06 |
诺华股份有限公司 |
慢病毒配制品
|
|
JP2026510999A
(ja)
|
2023-03-21 |
2026-04-10 |
バイオグラフ ５５，インク． |
Ｃｄ１９／ｃｄ３８多重特異性抗体
|
|
CN120981456A
(zh)
|
2023-05-24 |
2025-11-18 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
WO2025170844A1
(en)
*
|
2024-02-05 |
2025-08-14 |
Board Of Regents, The University Of Texas System |
Chimeric polypeptides and methods of use
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|